Redeye comments on W5 Solutions Q1-results which were better than expected, driven by solid topline ...
Redeye considers I-Tech’s Q1 report to be very solid, with an FX-adjusted growth of 7% y/y despite t...
Truecaller reported Q1 net sales exceeding our expectations and consensus by 3%.
SciBase’s Q1 report aligned closely with our projections.
Net sales was EUR 61m (Nordea est. EUR 69m) in Q1. Comparable net sales growth was -2% in Q1 y/y.
Yesterday, MHP provided the market with two news items: (1) the company announced the first German M...
Redeye returns with an update following Alligator Bioscience’s Q1 earnings release.
SRV’s Q1 figures were below expectations, with the low order backlog affecting both revenue and prof...
Redeye considers Nekkar’s Q1 report to be mixed, driven by a top-line growth of 17% y/y, which was b...
Q1 adjusted EBITDA of EUR 1.5m was clearly above our estimate of EUR 0.
Redeye comments on Freja’s Q1 report. As the solid ARR growth, slightly beating our expectations, wa...
Investors House reported Q1 revenues of EUR 1.5m, 11% below our estimate.
Redeye raises its Automotive estimates for Smart Eye ahead of the Q1 report following Seeing Machine...
CapMan's Q1 top-line figures and profitability both came in above our expectations.
Redeye provides a research update after Optomed’s Q1 2026 report.
Redeye comments on Cheffelo's Q1 2026 report, which delivered a quarterly EBIT of SEK35.
* Company confident about parrying input cost pressure * We make only minor estimate revisions * Acc...
Rising and scaling fee profit is in our view the key value driver for CapMan’s investment case and t...
Redeye comments on Invisio’s Q1-results where sales and order intake were close to our expectations ...
* EBITA SEK 260m (-2% vs. ABG, 0% vs. IR consensus) * We expect no material revisions to cons EBITA ...
